323578-37-6

Basic information

• Product Name: Carbamic acid, (6-methyl-3-pyridinyl)-, 1,1-dimethylethyl ester (9CI)
• Synonyms: Carbamic acid, (6-methyl-3-pyridinyl)-, 1,1-dimethylethyl ester (9CI);tert-butyl 6-methylpyridin-3-ylcarbamate;(6-Methyl-pyridin-3-yl)-carbaMic acid tert-butyl ester;tert-butyl N-(6-methylpyridin-3-yl)carbamate;tert-Butyl (6-methylpyridin-3-yl);Tert butyl 6- methyl pyridine -3- carbamate
• CAS NO: 323578-37-6
• Molecular Formula: C₁₁H₁₆N₂O₂
• Molecular Weight: 208.25694
• Product Categories: N-BOC
• Mol File: 323578-37-6.mol
• Article Data: 18

Chemical Properties

• Melting Point: 114-115 °C(Solv: hexane (110-54-3); ethyl acetate (141-78-6))
• Boiling Point: 262.7±28.0 °C(Predicted)
• Appearance: /
• Density: 1.108±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 12.94±0.70(Predicted)
• CAS DataBase Reference: Carbamic acid, (6-methyl-3-pyridinyl)-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, (6-methyl-3-pyridinyl)-, 1,1-dimethylethyl ester (9CI)(323578-37-6)
• EPA Substance Registry System: Carbamic acid, (6-methyl-3-pyridinyl)-, 1,1-dimethylethyl ester (9CI)(323578-37-6)

Safety Data

• Hazardous Substances Data: 323578-37-6(Hazardous Substances Data)

Usage

General Description

Carbamic acid, (6-methyl-3-pyridinyl)-, 1,1-dimethylethyl ester (9CI) is a chemical compound that is often used in the industry for varying applications. It belongs to the family of pyridine carboxamides and derivatives, which are compounds containing a pyridine ring, which is a six-membered aromatic heterocycle with a nitrogen atom, bearing a carboxamide group. The exact properties, such as the physical and chemical properties, toxicology and regulatory information about this compound might differ and therefore it is crucial to handle these chemicals with adequate precaution. The particular molecule features a 1,1-dimethylethyl ester moiety, suggesting it might be used in reactions related to ester exchange or conversions.

Upstream product

• 3222-47-7 6-methylnicotinic acid 
• 75-65-0 tert-butyl alcohol 
• 80287-53-2 5-Amino-2-methylpyridine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 3430-13-5 5-bromo-2-methylpyridine 
• 4248-19-5 tert-butyl carbazate 

Downstream Products

• 323578-38-7 tert-butyl N-[6-(hydroxymethyl)pyridin-3-yl]carbamate 
• 1150618-39-5 cis/trans-tert-butyl (6-methylpiperidin-3-yl)carbamate 
• 325457-93-0 3,4-difluoro-N-(6-methylpyridin-3-yl)-benzamide 
• 325458-32-0 3,4-difluoro-N-(6-trifluoromethylpyridin-3-yl)-benzamide 
• 1405129-10-3 tert-butyl ((3R,6R)-1-(3-((2-(2,6-difluorophenyl)imidazo[1,5-b]pyridazin-7-yl)amino)pyridin-4-yl)-6-methylpiperidin-3-yl)carbamate 
• 1405129-11-4 tert-butyl ((3S,6R)-1-(3-((2-(2,6-difluorophenyl)imidazo[1,5-b]pyridazin-7-yl)amino)pyridin-4-yl)-6-methylpiperidin-3-yl)carbamate 
• 1405129-12-5 tert-butyl ((3R,6S)-1-(3-((2-(2,6-difluorophenyl)imidazo[1,5-b]pyridazin-7-yl)amino)pyridin-4-yl)-6-methylpiperidin-3-yl)carbamate 
• 1405129-09-0 tert-butyl ((3S,6S)-1-(3-((2-(2,6-difluorophenyl)imidazo[1,5-b]pyridazin-7-yl)amino)pyridin-4-yl)-6-methylpiperidin-3-yl)carbamate 
• 1222491-53-3 1,1-dimethylethyl [6-methyl-3-piperidinyl]carbamate 
• 1222491-53-3 trans-tert-butyl N-(6-methyl-3-piperidyl)carbamate 

Relevant articles and documents

Preparation method of PF-06651600 intermediate

The invention relates to a preparation method of a PF-06651600 intermediate, and belongs to the field of medicinal chemistry. According to the method, 3-amino-6-methylpyridine can be used as a raw material, and a target compound is obtained through amino protection, quaternization, reduction, ketone formation, imine formation, reduction and amino protection. The method has the advantages of mild conditions, readily available reagents, high product purity, high yield and safe operation, and can be used for industrial production.

PYRROLO[2,3-D]PYRIMIDINE TOSYLATE SALT, CRYSTALLINE FORM THEREOF AND MANUFACTURING PROCESS AND INTERMEDIATES THERETO

The present invention discloses a novel p-toluenesulfonic acid salt and a crystalline polymorphic Form 1 of said salt of 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one, pharmaceutical composition containing the same, as well as preparations and uses thereof. The present invention also discloses a novel phosphoric acid salt of 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one, pharma-ceutical composition containing the same, as well as preparations and uses thereof.

Process Development and Scale up of a Selective JAK3 Covalent Inhibitor PF-06651600

A scalable process for PF-06651600 (1) has been developed through successful enabling of the first generation syntheis. The synthesis highlights include the following: (1) replacement of costly PtO2 with a less expensive 5% Rh/C catalyst for a pyridine hydrogenation, (2) identification of a diasteroemeric salt crystallization to isolate the enantiomerically pure cis-isomer directly from a racemic mixture of cis/trans isomers, (3) a high yielding amidation via Schotten-Baumann conditions, and (4) critical development of a reproducible crystallization procedure for a stable crystalline salt (1·TsOH), which is suitable for long-term storage and tablet formulation. All chromatographic purifications, including two chiral SFC chromatographic separations, were eliminated. Combined with other improvements in each step of the synthesis, the overall yield was increased from 5% to 14%. Several multikilogram batches of the API have been delivered to support clinical studies.